229.02 - 234.51
169.21 - 260.10
55.82M / 54.92M (Avg.)
32.24 | 7.26
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-12.88%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-12.81%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-20.65%
Negative EBIT growth while VUZI is at 20.01%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-20.65%
Negative operating income growth while VUZI is at 20.01%. Joel Greenblatt would press for urgent turnaround measures.
-16.66%
Negative net income growth while VUZI stands at 21.97%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-14.49%
Negative EPS growth while VUZI is at 22.73%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-14.71%
Negative diluted EPS growth while VUZI is at 22.73%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-2.84%
Share reduction while VUZI is at 0.65%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-2.80%
Reduced diluted shares while VUZI is at 0.65%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
17.86%
Dividend growth of 17.86% while VUZI is flat. Bruce Berkowitz would see if this can become a bigger advantage long term.
-4.24%
Negative OCF growth while VUZI is at 17.54%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
2.62%
FCF growth under 50% of VUZI's 14.82%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
804.23%
Positive 10Y revenue/share CAGR while VUZI is negative. John Neff might see a distinct advantage in product or market expansion over the competitor.
98.61%
5Y revenue/share CAGR above 1.5x VUZI's 48.43%. David Dodd would look for consistent product or market expansions fueling outperformance.
26.02%
3Y revenue/share CAGR above 1.5x VUZI's 14.83%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
1289.68%
10Y OCF/share CAGR above 1.5x VUZI's 69.05%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
143.77%
5Y OCF/share CAGR above 1.5x VUZI's 35.97%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
13.45%
3Y OCF/share CAGR at 75-90% of VUZI's 16.27%. Bill Ackman would press for improvements in margin or overhead to catch up.
1261.54%
Net income/share CAGR above 1.5x VUZI's 61.40% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
119.88%
5Y net income/share CAGR above 1.5x VUZI's 32.44%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
26.62%
Positive short-term CAGR while VUZI is negative. John Neff would see a clear advantage in near-term profit trajectory.
642.29%
10Y equity/share CAGR above 1.5x VUZI's 323.10%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
22.74%
Below 50% of VUZI's 216.40%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
7.35%
3Y equity/share CAGR 1.25-1.5x VUZI's 6.37%. Bruce Berkowitz confirms timely buybacks or margin improvements drive stronger near-term equity growth.
No Data
No Data available this quarter, please select a different quarter.
71.16%
Dividend/share CAGR of 71.16% while VUZI is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
40.43%
3Y dividend/share CAGR of 40.43% while VUZI is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
17.67%
Our AR growth while VUZI is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
-22.53%
Inventory is declining while VUZI stands at 28.99%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-4.98%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-6.75%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-5.94%
We’re deleveraging while VUZI stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
9.56%
We increase R&D while VUZI cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
-1.01%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.
